#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	1514	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2171	142.9	0	.	n	.	0	C207T	SNP	207	207	C	391	391	T	124	T,C	46,50	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	1514	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2171	142.9	0	.	n	.	0	C451T	SNP	451	451	C	635	635	T	147	T,C	61,54	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	1514	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2171	142.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1368	1368	C	220	C	159	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	1514	16S	1529	1529	99.87	16S.l6.c17.ctg.1	2171	142.9	0	HET	.	.	.	C1450T	.	1450	1450	C	1634	1634	C	197	C,T	69,72	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2904	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3573	164.1	0	.	n	.	0	T695C	SNP	695	695	T	1002	1002	C	197	C	141	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2904	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3573	164.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2278	2278	C	163	C	118	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2904	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3573	164.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2352	2352	A	164	A	117	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	2904	23S	2890	2890	99.93	23S.l15.c17.ctg.1	3573	164.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2904	2904	C	186	C	128	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	92	folP	855	855	100.0	folP.l15.c4.ctg.1	1541	11.9	1	SNP	p	R229S	1	.	.	685	687	AGC	897	899	AGC	19;19;19	A;G;C	15;15;15	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	795	272	gyrA	2751	2751	99.71	gyrA.l6.c4.ctg.1	4061	14.6	0	.	p	.	0	K780Q	NONSYN	2338	2340	AAA	2796	2798	CAA	7;7;7	C,A;A;A	0,2;3;5	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	795	272	gyrA	2751	2751	99.71	gyrA.l6.c4.ctg.1	4061	14.6	0	.	p	.	0	I781N	NONSYN	2341	2343	ATC	2799	2801	AAC	7;6;6	A;A,T;C	5;2,3;5	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	795	272	gyrA	2751	2751	99.71	gyrA.l6.c4.ctg.1	4061	14.6	1	SNP	p	S91F	1	.	.	271	273	TTC	729	731	TTC	23;23;23	T;T;C	16;15;16	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	795	272	gyrA	2751	2751	99.71	gyrA.l6.c4.ctg.1	4061	14.6	1	SNP	p	D95G	1	.	.	283	285	GGC	741	743	GGC	24;24;24	G;G;C	17;17;16	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	795	272	gyrA	2751	2751	99.71	gyrA.l6.c4.ctg.1	4061	14.6	1	SNP	p	G95N	0	.	.	283	285	GGC	741	743	GGC	24;24;24	G;G;C	17;17;16	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	92	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1328	15.1	1	SNP	p	G45D	0	.	.	133	135	GGC	466	468	GGC	29;29;29	G;G;C	23;23;23	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	96	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	813	22.4	0	.	n	.	0	A197.	DEL	197	197	A	469	469	A	34	A	27	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3571	21.0	1	SNP	p	D86N	0	.	.	256	258	GAC	977	979	GAC	42;42;42	G;A;C	26;27;29	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3571	21.0	1	SNP	p	S87R	1	.	.	259	261	CGT	980	982	CGT	42;42;41	C;G;T	31;28;28	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3571	21.0	1	SNP	p	R87I	0	.	.	259	261	CGT	980	982	CGT	42;42;41	C;G;T	31;28;28	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3571	21.0	1	SNP	p	R87W	0	.	.	259	261	CGT	980	982	CGT	42;42;41	C;G;T	31;28;28	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3571	21.0	1	SNP	p	S88P	0	.	.	262	264	TCC	983	985	TCC	41;41;40	T;C;C	30;30;29	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	254	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2768	19.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1441	1443	GGC	24;24;24	G;G;C	15;15;15	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	A311V	0	.	.	931	933	GCC	1230	1232	GCC	38;39;39	G;C;C	28;29;29	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	I312M	1	.	.	934	936	ATG	1233	1235	ATG	39;39;39	A;T;G	29;29;29	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	V316T	1	.	.	946	948	ACC	1245	1247	ACC	39;39;39	A;C;C	29;29;29	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	T316P	0	.	.	946	948	ACC	1245	1247	ACC	39;39;39	A;C;C	29;29;29	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1746	1748	ACC	21;21;21	A;C;C	16;15;16	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1800	1802	GCG	26;26;26	G;C;G	20;19;20	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1800	1802	GCG	26;26;26	G;C;G	20;19;20	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1923	1925	GGT	23;23;23	G;G;T,G	18;17;16,2	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1932	1934	AGC	26;26;25	A;G,A;C	17;18,1;17	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	278	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2303	23.7	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1950	1952	CCG	19;19;19	C;C;G	12;11;12	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	486	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3270	30.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1563	1565	CCG	23;23;22	C;C;G	15;17;13	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	158	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2227	15.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	653	653	C	21	C	14	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	252	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1658	31.4	1	SNP	p	G120K	1	.	.	358	360	AAG	763	765	AAG	34;34;34	A,G;A,G;G,T	26,1;26,1;25,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	252	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1658	31.4	1	SNP	p	N121D	0	.	.	361	363	AAC	766	768	AAC	34;34;34	A,G;A,C;C	25,1;26,1;27	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	252	porB1b	1038	1038	100.0	porB1b.l15.c4.ctg.1	1658	31.4	1	SNP	p	A121N	1	.	.	361	363	AAC	766	768	AAC	34;34;34	A,G;A,C;C	25,1;26,1;27	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	776	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5272	30.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	68	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1250	11.4	1	SNP	p	V57M	1	.	.	169	171	ATG	765	767	ATG	20;20;20	A;T;G	14;14;14	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
